within Pharmacolibrary.Drugs.ATC.L;

model L01XX44
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.1333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 4000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0025,
    k12             = 0.97,
    k21             = 0.97
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX44</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Aflibercept is a recombinant fusion protein acting as a decoy receptor for vascular endothelial growth factor (VEGF), inhibiting angiogenesis. It is approved for the treatment of various forms of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and certain cancers, including metastatic colorectal cancer. It is currently marketed under trade names such as Eylea (for ophthalmic use) and Zaltrap (for oncological use).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in cancer patients after intravenous administration of aflibercept (Zaltrap), as reported in adult men and women with metastatic colorectal cancer.</p><h4>References</h4><ol><li><p>Khayat, D, et al., &amp; Van Cutsem, E (2013). Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. <i>European journal of cancer (Oxford, England : 1990)</i> 49(4) 790–797. DOI:<a href=\"https://doi.org/10.1016/j.ejca.2012.10.012\">10.1016/j.ejca.2012.10.012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23312881/\">https://pubmed.ncbi.nlm.nih.gov/23312881</a></p></li><li><p>Syed, YY, &amp; McKeage, K (2015). Aflibercept: A Review in Metastatic Colorectal Cancer. <i>Drugs</i> 75(12) 1435–1445. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0444-4\">10.1007/s40265-015-0444-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26220913/\">https://pubmed.ncbi.nlm.nih.gov/26220913</a></p></li><li><p>Tew, WP, et al., &amp; Spriggs, DR (2014). Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> 120(3) 335–343. DOI:<a href=\"https://doi.org/10.1002/cncr.28406\">10.1002/cncr.28406</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24127346/\">https://pubmed.ncbi.nlm.nih.gov/24127346</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX44;
